Structural and chemical biology of presenilin complexes

Cold Spring Harbor Perspectives in Medicine

Volumn 7, Issue 12, 2017, Pages 25-

  Johnson, Douglas S ^a   Li, Yue Ming ^b   Pettersson, Martin ^a   St George Hyslop, Peter H ^c,d  

^a PFIZER INC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AVAGACESTAT; BIIB 042; E 2012; E 2212; EVP 0015962; FLURBIPROFEN; GAMMA SECRETASE INHIBITOR; GSI 256; GSI 529; GSM 1; GSM 2; ITANAPRACED; JNJ 40418677; JNJ 42601572; MK 0752; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NGP 555; NICASTRIN; NIROGACESTAT; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PRESENILIN 1; PRESENILIN 2; RO 02; SEMAGACESTAT; SP 53; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; CATALYSIS; COMPLEX FORMATION; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBUNIT; HUMAN; IC50; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; ANIMAL; CHEMISTRY; METABOLISM;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; PRESENILIN-1; PRESENILIN-2;

EID: 85030685313     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a024067     Document Type: Article

References (151)

1. Ahn K, Shelton CC, Tian Y, Zhang X, Gilchrist ML, Sisodia SS, Li YM. 2010. Activation and intrinsic γ-secretase activity of presenilin 1. Proc Natl Acad Sci 107: 21435-21440.
2. Andersson ER, Lendahl U. 2014. Therapeutic modulation of Notch signalling-Are we there yet? Nat Rev Drug Discov 13: 357-378.
3. Bai XC, Rajendra E, Yang G, Shi Y, Scheres SH. 2015a. Sampling the conformational space of the catalytic subunit of human γ-secretase. eLife 4: e11182.
4. Bai XC, Yan C, Yang G, Lu P, Ma D, Sun L, Zhou R, Scheres SH, Shi Y. 2015b. An atomic structure of human γ-secretase. Nature 525: 212-217.
5. Ballard TE, Murrey HE, Geoghegan KF, am Ende CW, Johnson DS. 2014. Investigating γ-secretase protein interactions in live cells using active site-directed clickable dual-photoaffinity probes. Med Chem Comm 5: 321-327.
6. Beher D, Fricker M, Nadin A, Clarke EE, Wrigley JD, Li YM, Culvenor JG, Masters CL, Harrison T, Shearman MS. 2003. In vitro characterization of the presenilin-dependent γ-secretase complex using a novel affinity ligand. Biochemistry 42: 8133-8142.
7. Bergman A, Laudon H, Winblad B, Lundkvist J, Naslund J. 2004. The extreme C terminus of presenilin 1 is essential for γ-secretase complex assembly and activity. J Biol Chem 279: 45564-45572.
8. Bischoff F, Berthelot D, De CM, MacDonald G, Minne G, Oehlrich D, Pieters S, Surkyn M, Trabanco AA, Tresadern G, et al. 2012. Design and synthesis of a novel series of bicyclic heterocycles as potent γ-secretase modulators. J Med Chem 55: 9089-9106.
9. Borgegard T, Jureus A, Olsson F, Rosqvist S, Sabirsh A, Rotticci D, Paulsen K, Klintenberg R, Yan H, Waldman M, et al. 2012. First and second generation γ-secretase modulators (GSMs) modulate amyloid-b (Ab) peptide production through different mechanisms. J Biol Chem 287: 11810-11819.
10. Brendel M, Jaworska A, Herms J, Trambauer J, Rotzer C, Gildehaus FJ, Carlsen J, Cumming P, Bylund J, Luebbers T, et al. 2015. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment. Mol Psychiatry 20: 1179-1187.
11. Chau DM, Crump CJ, Villa JC, Scheinberg DA, Li YM. 2012. Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase. J Biol Chem 287: 17288-17296.
12. Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H, et al. 2012. The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J 31: 2261-2274.
13. Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, Katayama T, Gu Y, Sanjo N, Glista M, Rogaeva E, et al. 2006. TMP21 is a presenilin complex component that modulates γ-secretase but not 1-secretase activity. Nature 440: 1208-1212.
14. Chun J, Yin YI, Yang G, Tarassishin L, Li YM. 2004. Stereoselective synthesis of photoreactive peptidomimetic γ-secretase inhibitors. J Org Chem 69: 7344-7347.
15. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, et al. 1997. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid b-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72.
16. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, et al. 2012. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69: 1430-1440.
17. Crump CJ, Fish BA, Castro SV, Chau DM, Gertsik N, Ahn K, Stiff C, Pozdnyakov N, Bales KR, Johnson DS, et al. 2011. Piperidine acetic acid based γ-secretase modulators directly bind to Presenilin-1. ACS Chem Neurosci 2: 705-710.
18. Crump CJ, am Ende CW, Ballard TE, Pozdnyakov N, Pettersson M, Chau DM, Bales KR, Li YM, Johnson DS. 2012a. Development of clickable active site-directed photoaffinity probes for γ-secretase. Bioorg Med Chem Lett 22: 2997-3000.
19. Crump CJ, Castro SV, Wang F, Pozdnyakov N, Ballard TE, Sisodia SS, Bales KR, Johnson DS, Li YM. 2012b. BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry 51: 7209-7211.
20. Crump CJ, Johnson DS, Li YM. 2013. Development and mechanism of γ-secretase modulators for Alzheimer’s disease. Biochemistry 52: 3197-3216.
21. DeAngelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I, Dallob A, Matthews C, Stone J, Freedman SJ, et al. 2006. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 24: 357S.
22. De Strooper B. 2014. Lessons from a failed γ-secretase Alzheimer trial. Cell 159: 721-726.
23. De Strooper B, Annaert W. 2010. Novel research horizons for presenilins and γ-secretases in cell biology and disease. Annu Rev Cell Dev Biol 26: 235-260.
24. De Strooper B, Annert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, et al. 1999. A presenilin dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature 398: 518-522.
25. Doan A, Thinakaran G, Borchelt DR, Slunt HH, Ratovitsky T, Podlisny M, Selkoe DJ, Seeger M, Gandy SE, Price DL, et al. 1996. Protein topology of presenilin 1. Neuron 17: 1023-1030.
26. D’Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A. 2012. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Discov 7: 19-37.
27. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, et al. 2013. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369: 341-350.
28. Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, Baumann K, Steiner H. 2011. Novel γ-secretase enzyme modulators directly target presenilin protein. J Biol Chem 286: 37181-37186.
29. Elad N, De Strooper B, Lismont S, Hagen W, Veugelen S, Arimon M, Horré K, Berezovska O, Sachse C, Chávez-Gutiérrez L. 2015. The dynamic conformational landscape of γ-secretase. J Cell Sci 128: 589-598.
30. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, et al. 2003. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Ab 42 in vivo. J Clin Invest 112: 440-449.
31. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Tsai JY, Rahmati T, Xia W, Selkoe DJ, Wolfe MS. 2000. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat Cell Biol 2: 428-434.
32. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS. 2002. Activity-dependent isolation of the preseniling-secretase complex reveals nicastrin and a g substrate. Proc Natl Acad Sci 99: 2720-2725.
33. 0 of the γ-secretase active site with (hydroxyethyl)urea peptidomimetics. Bioorg Med Chem Lett 14: 1935-1938.
34. Fagan R, Swindells M, Overington J, Weir M. 2001. Nicastrin, a presenilin-interacting protein, contains an aminopeptidase/transferrin receptor superfamily domain. Trends Biochem Sci 26: 213-214.
35. Findeis MA, Schroeder F, McKee TD, Yager D, Fraering PC, Creaser SP, Austin WF, Clardy J, Wang R, Selkoe D, et al. 2012. Discovery of a novel pharmacological and structural class of g secretase modulators derived from the extract of Actaea racemosa. ACS Chem Neurosci 3: 941-951.
36. Fluhrer R, Steiner H, Haass C. 2009. Intramembrane proteolysis by signal peptide peptidases: A comparative discussion of GXGD-type aspartyl proteases. J Biol Chem 284: 13975-13979.
37. Fortna RR, Crystal AS, Morais VA, Pijak DS, Lee VM, Doms RW. 2004. Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the gsecretase complex. J Biol Chem 279: 3685-3693.
38. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis MC, et al. 2002. aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of bAPP, and presenilin protein accumulation. Dev Cell 3: 85-97.
39. Friedmann E, Lemberg MK, Weihofen A, Dev KK, Dengler U, Rovelli G, Martoglio B. 2004. Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins. J Biol Chem 279: 50790-50798.
40. Gertsik N, Ballard TE, am Ende CW, Johnson DS, Li YM. 2014. Development of CBAP-BPyne, a probe for γ-secretase and presenilinase. Med Chem Comm 5: 338-341.
41. Gijsen HJ, Mercken M. 2012. γ-Secretase modulators: Can we combine potency with safety? Int J Alzheimer’s Dis: 295207.
42. Gillman KW, Starrett JE, Parker MF, Xie K, Bronson JJ, Marcin LR, McElhone KE, Bergstrom CP, Mate RA, Williams R, et al. 2010. Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable γ-secretase inhibitor. ACS Med Chem Lett 1: 120-124.
43. Gounder MM, Schwartz GK. 2012. Moving forward one Notch at a time. J Clin Oncol 30: 2291-2293.
44. Gu Y, Chen F, Sanjo N, Kawarai T, Hasegawa H, Duthie M, Li W, Ruan X, Luthra A, Mount HT, et al. 2003. APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin.nicastrin complexes. J Biol Chem 278: 7374-7380.
45. Gu Y, Sanjo N, Chen F, Hasegawa H, Petit A, Ruan X, Li W, Shier C, Kawarai T, Schmitt-Ulms G, et al. 2004. The presenilin proteins are components of multiple membrane-bound complexes that have different biological activities. J Biol Chem 279: 31329-31336.
46. Hall A, Patel TR. 2014. γ-Secretase modulators: Current status and future directions. Prog Med Chem 53: 101-145.
47. Hashimoto T, Ishibashi A, Hagiwara H, Murata Y, Takenaka O, Miyagawa T. 2010. E2012: A novel γ-secretase modulator-Pharmacology. Alzheimers Dement 6: S242.
48. Holmes O, Paturi S, Selkoe DJ, Wolfe MS. 2014. Pen-2 is essential for γ-secretase complex stability and trafficking but partially dispensable for endoproteolysis. Biochemistry 53: 4393-4406.
49. Huang X, Zhou W, Liu X, Li H, Sun G, Mandal M, Vicarel M, Zhu X, Bennett C, McCraken T, et al. 2012. Synthesis and SAR studies of fused oxadiazines as γ-secretase modulators for treatment of Alzheimer’s disease. ACS Med Chem Lett 3: 931-935.
50. Hubbs JL, Fuller NO, Austin WF, Shen R, Creaser SP, McKee TD, Loureiro RM, Tate B, Xia W, Ives J, et al. 2012. Optimization of a natural product-based class of γ-secretase modulators. J Med Chem 55: 9270-9282.
51. Hubbs JL, Fuller NO, Austin WF, Shen R, Ma J, Gong Z, Li J, McKee TD, Loureiro RM, Tate B, et al. 2015. Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of γ-secretase modulators. Bioorg Med Chem Lett 25: 1621-1626.
52. Imbimbo BP, Frigerio E, Breda M, Fiorentini F, Fernandez M, Sivilia S, Giardino L, Calza L, Norris D, Casula D, et al. 2013. Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. Alzheimer Dis Assoc Disord 27: 278-286.
53. Josien H. 2002. Recent advances in the development of γ-secretase inhibitors. Curr Opin Drug Discov Devel 5: 513-525.
54. Kim SH, Sisodia SS. 2005. A sequence within the first transmembrane domain of PEN-2 is critical for PEN-2-mediated endoproteolysis of presenilin 1. J Biol Chem 280: 1992-2001.
55. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. 2003. γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci 100: 6382-6387.
56. Kimura T, Kawano K, Doi E, Kitazawa N, Shin K, Miyagawa T, Kaneko T, Ito K, Takaishi M, Sasaki T, et al. 2005. Preparation of cinnamide, 3-benzylidenepiperidin-2-one, phenylpropynamide compounds as amyloid b production inhibitors. Eisai Co., Japan, pp. 679.
57. Kornilova AY, Das C, Wolfe MS. 2003. Differential effects of inhibitors on the γ-secretase complex. Mechanistic implications. J Biol Chem 278: 16470-16473.
58. Kornilova AY, Bihel F, Das C, Wolfe MS. 2005. The initial substrate-binding site of γ-secretase is located on presenilin near the active site. Proc Natl Acad Sci 102: 3230-3235.
59. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, et al. 2010. Modulation of γ-secretase reduces b-amyloid deposition in a transgenic mouse model of Alzheimer’s disease. Neuron 67: 769-780.
60. Krishnaswamy S. 2005. Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost 3: 54-67.
61. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, et al. 2012. Phase I pharmacologic and pharmacodynamic study of the g secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30: 2307-2313.
62. Lai MT, Chen E, Crouthamel MC, DiMuzio-Mower J, Xu M, Huang Q, Price E, Register RB, Shi XP, Donoviel DB, et al. 2003. Presenilin-1 and presenilin-2 exhibit distinct yet overlapping γ-secretase activities. J Biol Chem 278: 22475-22481.
63. Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, et al. 2006. Concentration-dependent modulation of amyloid-b in vivo and in vitro using the γ-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 319: 924-933.
64. Laudon H, Hansson EM, Melen K, Bergman A, Farmery MR, Winblad B, Lendahl U, von Heijne G, Naslund J. 2005. A nine-transmembrane domain topology for presenilin 1. J Biol Chem 280: 35352-35360.
65. Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, Li H. 2006. Electron microscopic structure of purified, active γ-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci 103: 6889-6894.
66. Lee SF, Shah S, Li H, Yu C, Han W, Yu G. 2002. Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-b precursor protein and Notch. J Biol Chem 277: 45013-45019.
67. Lee SF, Shah S, Yu C, Wigley WC, Li H, Lim M, Pedersen K, Han W, Thomas P, Lundkvist J, et al. 2004. A conserved GXXXG motif in APH-1 is critical for assembly and activity of the γ-secretase complex. J Biol Chem 279: 4144-4152.
68. Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Shafer JA, Gardell SJ. 2000a. Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state. Proc Natl Acad Sci 97: 6138-6143.
69. Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, et al. 2000b. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405: 689-694.
70. Li X, Dang S, Yan C, Gong X, Wang J, Shi Y. 2013. Structure of a presenilin family intramembrane aspartate protease. Nature 493: 56-61.
71. Li Y, Lu SH, Tsai CJ, Bohm C, Qamar S, Dodd RB, Meadows W, Jeon A, McLeod A, Chen F, et al. 2014. Structural interactions between inhibitor and substrate docking sites give insight into mechanisms of human PS1 complexes. Structure 22: 125-135.
72. Loureiro RM, Dumin JA, McKee TD, Austin WF, Fuller NO, Hubbs JL, Shen R, Jonker J, Ives J, Bronk BS, et al. 2013. Efficacy of SPI-1865, a novel γ-secretase modulator, in multiple rodent models. Alzheimers Res Ther 5: 19.
73. Lu SH, Jeon AH, Schmitt-Ulms G, Qamar S, Dodd R, McDonald B, Li Y, Meadows W, Cox K, Bohm C, et al. 2012a. Vigilin interacts with signal peptide peptidase. Proteome Sci 10: 33.
74. Lu Y, Riddell D, Hajos-Korcsok E, Bales K, Wood KM, Nolan CE, Robshaw AE, Zhang L, Leung L, Becker SL, et al. 2012b. Cerebrospinal fluid amyloid-b (Ab) as an effect biomarker for brain Ab lowering verified by quantitative preclinical analyses. J Pharmacol Exp Ther 342: 366-375.
75. Lu P, Bai XC, Ma D, Xie T, Yan C, Sun L, Yang G, Zhao Y, Zhou R, Scheres SH, et al. 2014. Three-dimensional structure of human γ-secretase. Nature 512: 166-170.
76. Mao G, Cui MZ, Li T, Jin Y, Xu X. 2012. Pen-2 is dispensable for endoproteolysis of presenilin 1, and nicastrin-Aph subcomplex is important for both γ-secretase assembly and substrate recruitment. J Neurochem 123: 837-844.
77. Martoglio B, Golde TE. 2003. Intramembrane-cleaving aspartic proteases and disease: Presenilins, signal peptide peptidase and their homologs. Hum Mol Genet 12: R201-R206.
78. Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, Matsuoka N. 2012. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 32: 2037-2050.
79. Nagy C, Schuck E, Ishibashi A, Nakatani Y, Rege B, Logovinsky V. 2010. E2012, a novel γ-secretase modulator, decreases plasma amyloid-b (Ab) levels in humans. Alzheimers Dement 6: S574.
80. Nakano-Ito K, Fujikawa Y, Hihara T, Shinjo H, Kotani S, Suganuma A, Aoki T, Tsukidate K. 2014. E2012-induced cataract and its predictive biomarkers. Toxicol Sci 137: 249-258.
81. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, Van Noort M, Hui CC, Clevers H, Dotto GP, Radtke F. 2003. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33: 416-421.
82. Nishimura M, Yu G, Levesque G, Zhang DM, Ruel L, Chen F, Milman P, Holmes E, Liang Y, Kawarai T, et al. 1999. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of b-catenin, a component of the presenilin protein complex. Nat Med 5: 164-169.
83. Oehlrich D, Rombouts FJ, Berthelot D, Bischoff FP, De Cleyn MA, Jaroskova L, Macdonald G, Mercken M, Surkyn M, Trabanco AA, et al. 2013. Design and synthesis of bicyclic heterocycles as potent γ-secretase modulators. Bioorg Med Chem Lett 23: 4794-4800.
84. Ogura T, Mio K, Hayashi I, Miyashita H, Fukuda R, Kopan R, Kodama T, Hamakubo T, Iwatsubo T, Tomita T, et al. 2006. Three-dimensional structure of the γ-secretase complex. Biochem Biophys Res Commun 343: 525-534.
85. Osenkowski P, Li H, Ye W, Li D, Aeschbach L, Fraering PC, Wolfe MS, Selkoe DJ. 2009. Cryoelectron microscopy structure of purified γ-secretase at 12 Å resolution. J Mol Biol 385: 642-652.
86. Overall CM. 2002. Molecular determinants of metalloproteinase substrate specificity: Matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 22: 51-86.
87. 42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and γ-secretase modulation. J Biol Chem 283: 677-683.
88. Page RM, Gutsmiedl A, Fukumori A, Winkler E, Haass C, Steiner H. 2010. β-amyloid precursor protein mutants respond to γ-secretase modulators. J Biol Chem 285: 17798-17810.
89. Pardossi-Piquard R, Yang SP, Kanemoto S, Gu Y, Chen F, Bohm C, Sevalle J, Li T, Wong PC, Checler F, et al. 2009. APH1 polar transmembrane residues regulate the assembly and activity of presenilin complexes. J Biol Chem 284: 16298-16307.
90. Peng H, Talreja T, Xin Z, Cuervo JH, Kumaravel G, Humora MJ, Xu L, Rohde E, Gan L, Jung MY, et al. 2011. Discovery of BIIB042, a potent, selective, and orally bioavailable γ-secretase modulator. ACS Med Chem Lett 2: 786-791.
91. 1-42 secretion. J Med Chem 48: 5705-5720.
92. Pettersson M, Kauffman GW, am Ende CW, Patel NC, Stiff C, Tran TP, Johnson DS. 2011. Novel γ-secretase modulators: A review of patents from 2008 to 2010. Expert Opin Ther Pat 21: 205-226.
93. Pettersson M, Stepan AF, Kauffman GW, Johnson DS. 2013. Novel γ-secretase modulators for the treatment of Alzheimer’s disease: A review focusing on patents from 2010 to 2012. Expert Opin Ther Pat 23: 1349-1366.
94. Pettersson M, Johnson DS, Subramanyam C, Bales KR, am Ende CW, Fish BA, Green ME, Kauffman GW, Mullins PB, Navaratnam T, et al. 2014. Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators. J Med Chem 57: 1046-1062.
95. Pettersson M, Johnson DS, Humphrey JM, Butler TW, am Ende CW, Fish BA, Green ME, Kauffman GW, Mullins PB, O’Donnell CJ, et al. 2015. Design of pyridopyrazine-1,6-dione γ-secretase modulators that align potency, MDR efflux ratio, and metabolic stability. ACS Med Chem Lett 6: 596-601.
96. Placanica L, Tarassishin L, Yang G, Peethumnongsin E, Kim SH, Zheng H, Sisodia SS, Li YM. 2009. Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 γ-secretase complexes. J Biol Chem 284: 2967-2977.
97. 299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue. Neurobiol Dis 3: 325-337.
98. Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K. 2010. Acute effect on the Ab isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 21: 1005-1012.
99. Pozdnyakov N, Murrey HE, Crump CJ, Pettersson M, Ballard TE, am Ende CW, Ahn K, Li YM, Bales KR, Johnson DS. 2013. γ-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem 288: 9710-9720.
100. Prokop S, Shirotani K, Edbauer D, Haass C, Steiner H. 2004. Requirement of PEN-2 for stabilization of the presenilin N-/C-terminal fragment heterodimer within the gsecretase complex. J Biol Chem 279: 23255-23261.
101. Renzi F, Zhang X, Rice WJ, Torres-Arancivia C, Gomez-Llorente Y, Diaz R, Ahn K, Yu C, Li YM, Sisodia SS, et al. 2011. Structure of γ-secretase and its trimeric preactivation intermediate by single-particle electron microscopy. J Biol Chem 286: 21440-21449.
102. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. 1995. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 376: 775-778.
103. Rogers K, Felsenstein KM, Hrdlicka L, Tu Z, Albayya F, Lee W, Hopp S, Miller MJ, Spaulding D, Yang Z, et al. 2012. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener 7: 61.
104. Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK, De Baets G, De Wever V, Habets R, Baert V, et al. 2016. Restricted location of PSEN2/gsecretase determines substrate specificity and generates an intracellular Ab pool. Cell 166: 193-208.
105. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al. 1996. Secreted amyloid b-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2: 864-870.
106. Serneels L, Dejaegere T, Craessaerts K, Horre K, Jorissen E, Tousseyn T, Hebert S, Coolen M, Martens G, Zwijsen A, et al. 2005. Differential contribution of the three Aph1 genes to γ-secretase activity in vivo. Proc Natl Acad Sci 102: 1719-1724.
107. Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, Van Houtvin T, Esselmann H, Paul S, Schafer MK, Berezovska O, et al. 2009. γ-Secretase heterogeneity in the Aph1 subunit: Relevance for Alzheimer’s disease. Science 324: 639-642.
108. Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, Laplant Q, Ball H, Dann CE III, Sudhof T, Yu G. 2005. Nicastrin functions as a γ-secretase-substrate receptor. Cell 122: 435-447.
109. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, Castro JL. 2000. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid b-protein precursor gsecretase activity. Biochemistry 39: 8698-8704.
110. Shelton CC, Zhu L, Chau D, Yang L, Wang R, Djaballah H, Zheng H, Li YM. 2009. Modulation of γ-secretase specificity using small molecule allosteric inhibitors. Proc Natl Acad Sci 106: 20228-20233.
111. Shen J, Kelleher RJ III. 2007. The presenilin hypothesis of Alzheimer’s disease: Evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci 104: 403-409.
112. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. 1995. Cloning of a gene bearing missense mutations in earlyonset familial Alzheimer’s disease. Nature 375: 754-760.
113. Shirotani K, Edbauer D, Capell A, Schmitz J, Steiner H, Haass C. 2003. γ-Secretase activity is associated with a conformational change of nicastrin. J Biol Chem 278: 16474-16477.
114. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. 2007. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-b after inhibition of γ-secretase. Clin Neuropharmacol 30: 317-325.
115. Sobhanifar S, Schneider B, Lohr F, Gottstein D, Ikeya T, Mlynarczyk K, Pulawski W, Ghoshdastider U, Kolinski M, Filipek S, et al. 2010. Structural investigation of the C-terminal catalytic fragment of presenilin 1. Proc Natl Acad Sci 107: 9644-9649.
116. Spasic D, Raemaekers T, Dillen K, Declerck I, Baert V, Serneels L, Fullekrug J, Annaert W. 2007. Rer1p competes with APH-1 for binding to nicastrin and regulates gsecretase complex assembly in the early secretory pathway. J Cell Biol 176: 629-640.
117. Steiner H, Fluhrer R, Haass C. 2008. Intramembrane proteolysis by γ-secretase. J Biol Chem 283: 29627-29631.
118. Sun ZY, Asberom T, Bara T, Bennett C, Burnett D, Chu I, Clader J, Cohen-Williams M, Cole D, Czarniecki M, et al. 2012. Cyclic hydroxyamidines as amide isosteres: Discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo. J Med Chem 55: 489-502.
119. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T. 2003. The role of presenilin cofactors in the γ-secretase complex. Nature 422: 438-441.
120. Takeo K, Tanimura S, Shinoda T, Osawa S, Zahariev IK, Takegami N, Ishizuka-Katsura Y, Shinya N, Takagi-Niidome S, Tominaga A, et al. 2014. Allosteric regulation of γ-secretase activity by a phenylimidazole-type gsecretase modulator. Proc Natl Acad Sci 111: 10544-10549.
121. Tarassishin L, Yin YI, Bassit B, Li YM. 2004. Processing of Notch and amyloid precursor protein by γ-secretase is spatially distinct. Proc Natl Acad Sci 101: 17050-17055.
122. Teranishi Y, Hur JY, Welander H, Franberg J, Aoki M, Winblad B, Frykman S, Tjernberg LO. 2010. Affinity pulldown of γ-secretase and associated proteins from human and rat brain. J Cell Mol Med 14: 2675-2686.
123. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, et al. 1996. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17: 181-190.
124. Tian G, Sobotka-Briner CD, Zysk J, Liu X, Birr C, Sylvester MA, Edwards PD, Scott CD, Greenberg BD. 2002. Linear non-competitive inhibition of solubilized human gsecretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J Biol Chem 277: 31499-31505.
125. Tian Y, Bassit B, Chau D, Li YM. 2010. An APP inhibitory domain containing the Flemish mutation residue modulates γ-secretase activity for Ab production. Nat Struct Mol Biol 17: 151-158.
126. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, et al. 2012. Phase I study of RO4929097, a g secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30: 2348-2353.
127. Toyn JH, Thompson LA, Lentz KA, Meredith JE Jr, Burton CR, Sankaranararyanan S, Guss V, Hall T, Iben LG, Krause CM, et al. 2014. Identification and preclinical pharmacology of the γ-secretase modulator BMS-869780. Int J Alzheimers Dis 2014: 431858.
128. Tran TP, Mullins PB, am Ende CW, Pettersson M. 2013. Synthesis of pyridopyrazine-1,6-diones from 6-hydroxypicolinic acids via a one-pot coupling/cyclization reaction. Org Lett 15: 642-645.
129. Van Broeck B, Chen JM, Tréton G, Desmidt M, Hopf C, Ramsden N, Karran E, Mercken M, Rowley A. 2011. Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer’s disease. Br J Pharmacol 163: 375-389.
130. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, et al. 2005. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963.
131. Villa JC, Chiu D, Brandes AH, Escorcia FE, Villa CH, Maguire WF, Hu CJ, de Stanchina E, Simon MC, Sisodia SS, et al. 2014. Nontranscriptional role of Hif-1a in activation of γ-secretase and notch signaling in breast cancer. Cell Rep 8: 1077-1092.
132. Wagner SL, Tanzi RE, Mobley WC, Galasko D. 2012. Potential use of γ-secretase modulators in the treatment of Alzheimer disease. Arch Neurol 69: 1255-1258.
133. Watanabe N, Tomita T, Sato C, Kitamura T, Morohashi Y, Iwatsubo T. 2005. Pen-2 is incorporated into the γ-secretase complex through binding to transmembrane domain 4 of presenilin 1. J Biol Chem 280: 41967-41975.
134. Watanabe N, Takagi S, Tominaga A, Tomita T, Iwatsubo T. 2010. Functional analysis of the transmembrane domains of presenilin 1: Participation of transmembrane domains 2 and 6 in the formation of initial substrate-binding site of γ-secretase. J Biol Chem 285: 19738-19746.
135. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al. 2001. A subset of NSAIDs lower amyloidogenic Ab42 independently of cyclooxygenase activity. Nature 414: 212-216.
136. Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B. 2002. Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 296: 2215-2218.
137. Wolfe MS. 2013. Toward the structure of presenilin/γ-secretase and presenilin homologs. Biochim Biophys Acta 1828: 2886-2897.
138. Wolfe MS, Xia W, Moore CL, Leatherwood DD, Ostaszewski B, Rahmati T, Donkor IO, Selkoe DJ. 1999a. Peptidomimetic probes and molecular modeling suggest that Alzheimer’s γ-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry 38: 4720-4727.
139. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DS. 1999b. Two transmembrane aspartates in presenilin 1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398: 513-517.
140. Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang XJ, Koo EH, Wu X, Zheng H. 2001. Loss of presenilin 1 is associated with enhanced b-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci 98: 10863-10868.
141. Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, Bolshakov VY, Shen J, Kelleher RJ III. 2015. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer’s disease. Neuron 85: 967-981.
142. Xie T, Yan C, Zhou R, Zhao Y, Sun L, Yang G, Lu P, Ma D, Shi Y. 2014. Crystal structure of the γ-secretase component nicastrin. Proc Natl Acad Sci 111: 13349-13354.
143. Xu M, Lai MT, Huang Q, DiMuzio-Mower J, Castro JL, Harrison T, Nadin A, Neduvelil JG, Shearman MS, Shafer JA, et al. 2002. γ-Secretase: Characterization and implication for Alzheimer disease therapy. Neurobiol Aging 23: 1023-1030.
144. Yang DS, Tandon A, Chen F, Yu G, Yu H, Arawaka S, Hasegawa H, Duthie M, Schmidt SD, Ramabhadran TV, et al. 2002. Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins. J Biol Chem 277: 28135-28142.
145. Yang G, Yin YI, Chun J, Shelton CC, Ouerfelli O, Li YM. 2009. Stereo-controlled synthesis of novel photoreactive γ-secretase inhibitors. Bioorg Med Chem Lett 19: 922-925.
146. Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM. 2007. γ-Secretase substrate concentration modulates the Ab42/ Ab40 ratio: Implications for Alzheimer disease. J Biol Chem 282: 23639-23644.
147. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, Song YQ, Rogaeva E, Chen F, Kawarai T, et al. 2000. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and bAPP processing. Nature 407: 48-54.
148. Yu Y, Logovinsky V, Schuck E, Kaplow J, Chang MK, Miyagawa T, Wong N, Ferry J. 2014. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects. J Clin Pharmacol 54: 528-536.
149. Zhang YW, Luo WJ, Wang H, Lin P, Vetrivel KS, Liao F, Li F, Wong PC, Farquhar MG, Thinakaran G, et al. 2005. Nicastrin is critical for stability and trafficking but not association of other presenilin/γ-secretase components. J Biol Chem 280: 17020-17026.
150. Zhang X, Yu CJ, Sisodia SS. 2015. The topology of pen-2, a γ-secretase subunit, revisited: Evidence for a reentrant loop and a single pass transmembrane domain. Mol Neurodegener 10: 39.
151. Zhao G, Liu Z, Ilagan MX, Kopan R. 2010. γ-Secretase composed of PS1/Pen2/Aph1a can cleave notch and amyloid precursor protein in the absence of nicastrin. J Neurosci 30: 1648-1656.